Data Sharing and Data Privacy - what every statistician needs to know
Data sharing, data transparency and data privacy are areas that continue to evolve. For example, EMA Policy 70 is now effective with proactive publication of submitted clinical overviews and study reports. It is becoming more common for clinical trial data to be used to support scientific questions beyond the objectives of the original study.
The intent of this webinar is to provide an outline to pharmaceutical statisticians of key issues and concepts everyone dealing with and sharing patient level data should be aware of.
Presentation #1 Sharing clinical trial data externally – key data privacy concepts every statistician should know (Janice Branson and Nicola Orlandi (Novartis)) Click here to view the slides
Presentation #2 Data Sources to help inform drug development – what you give is also what you get (Sally Hollis (Phastar) and Rebecca Sudlow (Roche)) Click here to view the slides
Data Sharing and Data Privacy - what every statistician needs to know
Data sharing, data transparency and data privacy are areas that continue to evolve. For example, EMA Policy 70 is now effective with proactive publication of submitted clinical overviews and study reports. It is becoming more common for clinical trial data to be used to support scientific questions beyond the objectives of the original study.
The intent of this webinar is to provide an outline to pharmaceutical statisticians of key issues and concepts everyone dealing with and sharing patient level data should be aware of.
Presentation #1 Sharing clinical trial data externally – key data privacy concepts every statistician should know (Janice Branson and Nicola Orlandi (Novartis)) Click here to view the slides
Presentation #2 Data Sources to help inform drug development – what you give is also what you get (Sally Hollis (Phastar) and Rebecca Sudlow (Roche)) Click here to view the slides
Data Sharing and Data Privacy - what every statistician needs to know
Data sharing, data transparency and data privacy are areas that continue to evolve. For example, EMA Policy 70 is now effective with proactive publication of submitted clinical overviews and study reports. It is becoming more common for clinical trial data to be used to support scientific questions beyond the objectives of the original study.
The intent of this webinar is to provide an outline to pharmaceutical statisticians of key issues and concepts everyone dealing with and sharing patient level data should be aware of.
Presentation #1 Sharing clinical trial data externally – key data privacy concepts every statistician should know (Janice Branson and Nicola Orlandi (Novartis)) Click here to view the slides
Presentation #2 Data Sources to help inform drug development – what you give is also what you get (Sally Hollis (Phastar) and Rebecca Sudlow (Roche)) Click here to view the slides
Data Sharing and Data Privacy - what every statistician needs to know
Data sharing, data transparency and data privacy are areas that continue to evolve. For example, EMA Policy 70 is now effective with proactive publication of submitted clinical overviews and study reports. It is becoming more common for clinical trial data to be used to support scientific questions beyond the objectives of the original study.
The intent of this webinar is to provide an outline to pharmaceutical statisticians of key issues and concepts everyone dealing with and sharing patient level data should be aware of.
Presentation #1 Sharing clinical trial data externally – key data privacy concepts every statistician should know (Janice Branson and Nicola Orlandi (Novartis)) Click here to view the slides
Presentation #2 Data Sources to help inform drug development – what you give is also what you get (Sally Hollis (Phastar) and Rebecca Sudlow (Roche)) Click here to view the slides
Data Sharing and Data Privacy - what every statistician needs to know
Data sharing, data transparency and data privacy are areas that continue to evolve. For example, EMA Policy 70 is now effective with proactive publication of submitted clinical overviews and study reports. It is becoming more common for clinical trial data to be used to support scientific questions beyond the objectives of the original study.
The intent of this webinar is to provide an outline to pharmaceutical statisticians of key issues and concepts everyone dealing with and sharing patient level data should be aware of.
Presentation #1 Sharing clinical trial data externally – key data privacy concepts every statistician should know (Janice Branson and Nicola Orlandi (Novartis)) Click here to view the slides
Presentation #2 Data Sources to help inform drug development – what you give is also what you get (Sally Hollis (Phastar) and Rebecca Sudlow (Roche)) Click here to view the slides
Data Sharing and Data Privacy - what every statistician needs to know
Data sharing, data transparency and data privacy are areas that continue to evolve. For example, EMA Policy 70 is now effective with proactive publication of submitted clinical overviews and study reports. It is becoming more common for clinical trial data to be used to support scientific questions beyond the objectives of the original study.
The intent of this webinar is to provide an outline to pharmaceutical statisticians of key issues and concepts everyone dealing with and sharing patient level data should be aware of.
Presentation #1 Sharing clinical trial data externally – key data privacy concepts every statistician should know (Janice Branson and Nicola Orlandi (Novartis)) Click here to view the slides
Presentation #2 Data Sources to help inform drug development – what you give is also what you get (Sally Hollis (Phastar) and Rebecca Sudlow (Roche)) Click here to view the slides
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
PSI Webinar: Development of Gene Therapies: Strategic, Scientific, Regulatory and Access Considerations
This webinar will cover the history of cell/gene therapy, major regulatory advances, the role of quantitative scientists in drug development of these novel therapeutics, and discuss opportunities for innovation and product advancement.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Introduction to Industry Training (ITIT) Course - 2024/2025
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
PSI Training Course: Regulatory Guidelines for Statisticians
This 2-day course is designed to provide a comprehensive understanding of the regulatory guidelines affecting statisticians in the pharmaceutical industry, including the latest updates in the field. The course will cover key International Council for Harmonisation (ICH) guidelines and other key regional regulatory agency documents.
Joint PSI/EFSPI Pre-Clinical SIG Webinar: Virtual Control Groups in Toxicity Studies
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This apprenticeship role offers a unique opportunity to learn and work in a global healthcare consultancy company alongside a team of statisticians, psychometricians and programmers.
Statisticians in the Pharmaceutical Industry Executive Office: c/o MCI UK Ltd | Unit 24/22 South | Building 4000 | Langstone Park| Langstone Road | Havant | PO9 1SA | UK